Next, we assessed the ability of the IgG1‐format Ars2 BAR‐bodies to bind specifically to the B‐cell lymphoma cell lines U2932 and OCI‐Ly3 that are known to express Ars2‐reactive BCRs. This evidence concerns the gene SRRT and B-cell non-Hodgkin lymphoma.